





Sub
A1
moieties), primary, secondary, tertiary or quaternary amino-containing moieties, pyridinium-containing moieties, guanidinium-containing moieties, amidinium-containing moieties, phenol-containing moieties, heterocycles possessing acidic or basic hydrogens, and zwitterionic-containing moieties.

10. (Amended) A method according to claim 1, wherein in said compound the moiety or moieties which are bonded to amino or other reactive terminal groups of the dendrimer are selected from the following groups, in which n is zero or a positive integer:





























09786972.054401
TOT 50 269860


Sub
A1
Cont


$$\text{---Ar[B(OH)}_2\text{]}_n \quad n=1-3 \qquad \text{---Ar[COOH]}_n \quad n=1-3$$


09786972-051101

Sub
A-1
Cmt





R = alkyl or arylalkyl; R₁, R₂, R₃ (which may be same or different) = alkyl or arylalkyl



11. (Amended) A method according to claim 1, wherein said compound is selected from the group consisting of:

- i. alkylsulfonic acid terminated dendrimers;
- ii. sulfoacetamide terminated dendrimers;
- iii. sulfosuccinamic acid terminated dendrimers;
- iv. N-(2-sulfoethyl) succinamide terminated dendrimers;
- v. 4-sulfophenylthiourea terminated dendrimers;
- vi. 3,6-di-sulfonaphthylthiourea terminated dendrimers;
- vii. 4-sulfonaphthylthiourea terminated dendrimers;
- viii. 3,5-di-sulfophenylthiourea terminated dendrimers;
- ix. 3,6,8-tri-sulfonaphthylthiourea terminated dendrimers;
- x. 4-(sulfomethyl) benzamide terminated dendrimers;
- xi. 4-sulfobenzamide terminated dendrimers;
- xii. N-(4-sulfophenyl) propanamide terminated dendrimers;
- xiii. 4-sulfophenylurea terminated dendrimers;
- xiv. N,N,N-tri-methylglycinamide terminated dendrimers;
- xv. 4-trimethylammonium benzamide terminated dendrimers;
- xvi. 4-(trimethylammoniummethyl)benzamide terminated dendrimers;

- Al
Cmt
- xvii. N-(2-acetoxyethyl)-N,N-(dimethylammonium)methyl-carboxamide terminated dendrimers;
 - xviii. guanidino terminated dendrimers;
 - xix. 4-([1,4,8,11-tetraazacyclotetradecane]methyl)benzamide terminated dendrimers;
 - xx. 4-carboxy-3-hydroxy-benzylamine terminated dendrimers;
 - xxi. 4-carboxyphenylamide terminated dendrimers;
 - xxii. 3,5-dicarboxyphenylamide terminated dendrimers;
 - xxiii. 4-phosphonooxyphenylthiourea terminated dendrimers;
 - xxiv. 4-(phosphonomethyl)phenylthiourea terminated dendrimers;
 - xxv. ethyl-4-(phosphonomethyl)phenylthiourea terminated dendrimers;
 - xxvi. (8-octanamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
 - xxvii. (11-undecanamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
 - xxviii. (acetamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
 - xxix. (4-butanamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
 - xxx. (4-methylbenzamido)-5-acetamido-3,5-dideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
 - xxxi. (8-octanamido)-4-azido-5-acetamido-3,4,5-trideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
 - xxxii. (8-octanamido)-4-amino-5-acetamido-3,4,5-trideoxy-2-thio-D-glycero- β -D-galacto-2-nonulopyranosidoic acid terminated dendrimers;
 - xxxiii. 4-benzamidoboronic acid terminated dendrimers;
 - xxxiv. 3,5-dicarboxyphenylthiourea terminated dendrimers;
 - xxxv. 4-phosphonooxyphenylthiourea terminated dendrimers;
 - xxxvi. 4-phosphonophenylthiourea terminated dendrimers;
 - xxxvii. 4,6-diphosphononaphthylthiourea terminated dendrimers;
 - xxxviii. fluoresceinithiourea terminated dendrimers;
 - xxxix. (phenyl-3-boronic acid)-thiourea terminated dendrimers;
 - xl. pyridinium dodecylcarboxamide terminated dendrimers; and

~~xii. saccharin terminated dendrimers.~~

Al
Cmt

12. (Amended) A method according to claim 1, wherein said treatment comprises inhibition of toxins and toxic peptides of biological origin or toxins and toxic peptides released during bacterial, protozoal, fungal or viral infection.

13. (Amended) A pharmaceutical or veterinary composition for prophylactic or therapeutic inhibition of a toxic material or substance in a human or non-human animal, which comprises an anionic or cationic dendrimer as defined in any of claims 1 to 11, in association with at least one pharmaceutically or veterinarily acceptable carrier or diluent.

REMARKS

Applicants respectfully request that the foregoing amendments to Claims 8-13 be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims.